What Grade 4 knee cartilage damage actually means

A scan report saying 'Grade 4 cartilage damage' is understandably alarming — but the grade describes the depth of the injury, not a single fixed outcome or a predetermined treatment path.

The ICRS (International Cartilage Repair Society) classification — broadly equivalent to the older Outerbridge system — grades cartilage damage from 1 to 4. Grade 4 is the most severe: full-thickness loss of articular cartilage, with the underlying subchondral bone exposed. Because articular cartilage has no blood supply and no nerve fibres, it cannot repair itself in any meaningful way; a focal Grade 4 defect will persist, or fill at best with structurally inferior fibrocartilage, without intervention.

Grade 4 is not, however, a single uniform problem. A small, sharply defined 1.5 cm² lesion on the medial femoral condyle in a 32-year-old is a fundamentally different clinical scenario from a 10 cm² defect involving both articular surfaces, even though both carry the same grade label. Defect size — measured in cm² on MRI — is the next critical variable, and the one that most directly determines which repair strategies are structurally adequate. Bone involvement matters too: cysts or damage beneath the cartilage surface narrow the field of options further, since not all techniques can address the bony layer.

Symptoms alone do not reliably indicate how large or deep a defect is. MRI with cartilage-sensitive sequences is the appropriate next step to map the defect precisely before any treatment decision is made.

Why defect size and bone depth come before technique preference

Three clinical facts come before any technique discussion, and they are not interchangeable with preference.

Defect size sets the first boundary. Focal lesions smaller than roughly 3 cm² with no bone loss may be suitable for an injectable collagen scaffold approach; the 2–8 cm² range with structurally intact subchondral bone is the typical territory for single-stage surgical repair such as AMIC; and lesions larger than approximately 3–4 cm² where bone is also damaged — or where previous cartilage surgery has already failed — generally point toward osteochondral allograft (OCA), which replaces both cartilage and bone in a single graft. These thresholds are indicative, not absolute, and overlap at the margins.

Bone involvement is a disqualifying factor for surface-only techniques. A scaffold or marrow-stimulation procedure acts at the cartilage layer; it cannot restore a cystic or resorbed subchondral bed. Where bone loss is present, any technique that ignores it is structurally inadequate.

Prior failed cartilage surgery shifts the picture independently of current defect size. A re-do situation after microfracture or an earlier scaffold repair typically requires a more structurally comprehensive approach than the same defect would demand in a treatment-naïve joint.

Finally, diffuse or advanced OA across the compartment places a patient outside the scope of focal cartilage repair altogether — none of these three techniques is indicated when damage is widespread rather than focal.

A consultant assessment with cartilage-sensitive MRI is what determines which category applies. The rest of this article assumes that assessment has narrowed the picture to a focal, repairable defect.

ChondroFiller injection: the outpatient scaffold pathway

For patients with a focal Grade 4 lesion where the subchondral bone is reasonably intact and surrounding cartilage is healthy, ChondroFiller injection offers a markedly different procedural profile from the surgical options described above: an outpatient treatment delivered under local anaesthesia via ultrasound guidance, with same-day discharge and no requirement for general anaesthesia or a theatre environment.

The treatment uses a CE-marked, acellular Type I collagen hydrogel supplied as a two-chamber syringe. Once placed into the cartilage defect under image guidance, it polymerises within three to five minutes, forming a stable three-dimensional scaffold. The mechanism is matrix-induced chondrogenesis: the scaffold recruits the patient's own progenitor cells to migrate into the matrix and differentiate toward cartilage repair tissue. No donor cells are introduced — the biology depends on what the patient's joint provides.

Published clinical evidence in the knee includes a prospective study of 17 patients (mean age 31), in which ChondroFiller was delivered arthroscopically as an earlier delivery route, reporting significant improvements in Lysholm and IKDC scores at 3, 6, and 12 months (p<0.05). Scores stabilised between the six- and twelve-month timepoints, suggesting durable early benefit rather than continued incremental gain. A 2025 prospective controlled trial specifically evaluated ChondroFiller combined with a blood-derived stem cell-rich graft in Grade IV knee osteoarthritis — a clinically relevant design — though the trial's complete outcome results have not yet been published.

Compared with AMIC or OCA, ChondroFiller's evidence base is smaller in volume and shorter in follow-up duration — single-centre studies, modest sample sizes, no published head-to-head RCT — which matters for informed consent without disqualifying the treatment for appropriate patients. Expectations should remain anchored to what the existing data demonstrate.

AMIC: one-stage surgical repair for medium focal lesions

Surgical but single-stage, AMIC (Autologous Matrix-Induced Chondrogenesis) sits in the repair tier for focal lesions in the 2–8 cm² range — larger than an injectable scaffold can reliably address, but not yet requiring a full structural allograft.

The procedure combines subchondral microfracture — perforating the bone to release marrow-derived progenitor cells into the defect — with immediate coverage by a bioresorbable collagen Type I/III scaffold (Chondro-Gide, Geistlich). The scaffold stabilises the marrow clot and guides recruited cells toward hyaline-like repair tissue. It is performed in a single operating episode, arthroscopically or via a mini-open approach, under general or regional anaesthesia.

The evidence base is the most developed of the three techniques discussed in this article. A 10-year prospective RCT (47 patients) found both sutured and glued AMIC maintained stable Modified Cincinnati Knee Scores at the decade mark, while the microfracture-alone group deteriorated significantly from year two onward. Seven-year follow-up in 21 patients supports efficacy for defects above 2 cm², and a 48-patient matched-pair study found two-year outcomes equivalent to MACI and minced cartilage implantation. A 2025 European multicentre study of 27 adolescents (ICRS grade III/IV, mean defect 2.3 cm²) showed KOOS pain improvement from 58% to 87% and sports/leisure from 29% to 73% at 2.6 years (all p<0.001). The AMIC Registry — 57 patients, mean defect 3.4 cm² — confirmed significant VAS pain reduction and functional gains at one and two years post-surgery.

'One-stage' refers to the operating episode, not a brief recovery. Protected weight-bearing typically runs for six to eight weeks; return to sport is generally expected in the region of 9–12 months — a timeline reflected in a case report of a professional footballer who reached a Lysholm score of 90 and returned to competition at ten months following AMIC for a 3 cm² Grade IV femoral condyle lesion.

The central limitation: AMIC stimulates marrow-cell recruitment at the cartilage surface but cannot structurally restore damaged subchondral bone. Where deep bone loss is present, this disqualifies the technique rather than refines it.

OCA: structural allograft for large or previously failed defects

Of the three approaches covered here, OCA (osteochondral allograft transplantation) is the only one that addresses the bone as well as the cartilage surface. A matched donor plug — fresh allograft containing live hyaline cartilage and its underlying subchondral bone — is press-fitted into the defect during open surgery under general anaesthesia. That structural depth is precisely why OCA is reserved for defects above approximately 3–4 cm² with bone involvement, or as a salvage procedure when prior cartilage surgery has failed and the underlying architecture has been further compromised.

Return-to-sport data provide a useful benchmark: across 14 studies covering 471 athletes, 72% returned to sport following OCA, with 84% of those returning at an equal or higher level at a weighted mean of 11.1 months. These figures are informative, but they reflect a selected population treated at specialist centres.

Survivorship data for more complex presentations require honest reading. In a primary knee OCA cohort of 186 cases, the overall failure rate was 23.1%, driven by OCA bone failure (34.9% of failures), meniscus-related failure (30.2%), and joint disease progression (25.6%). For large bipolar lesions — mean defect 16.7 cm² across 89 knees — graft failure reached 34.8% and survivorship fell to 73.8% at five years and 58.9% at 15 years, with a mean time to failure of 4.8 years. When OCA is deployed as a salvage procedure after failed index cartilage surgery (349 patients, mean defect 5.8 cm²), the overall failure rate was 16.6%, five-year survival was 79–87.8%, and ten-year survival was 61–82% — worsening sharply for defects above 9–10 cm², where reoperation rates approached 67%.

The risk modifiers shaping these outcomes are well-characterised and directly usable in patient-selection discussions: smoking, high BMI, bipolar joint involvement, concurrent ligament reconstruction, increasing defect size, and older age each independently worsen prognosis. Post-operative knee range of motion generally recovers above 120°, with biomechanical outcomes broadly comparable to ACI in published series.

Two practical constraints sit alongside the clinical ones. OCA requires inpatient admission, open surgery, and approximately six weeks of protected weight-bearing. It is also contingent on donor graft availability — a logistical factor that can affect timing in ways that other techniques do not.

Choosing between the three: what guides the decision in practice

Direct comparison between ChondroFiller injection, AMIC, and OCA in a single randomised trial has not been done for Grade 4 knee lesions. Clinical selection is guided by technique-specific evidence matched, step by step, to the patient and defect — not by comparative trial data.

The decision sequence runs in a fixed order. Defect size and subchondral bone integrity come first — these two variables, established in the earlier sections, determine which techniques remain viable before any patient preference enters the picture. The filter then shifts to history: a patient who has already undergone cartilage surgery and sustained further bone compromise sits in a different position from someone presenting with an isolated focal lesion for the first time. Patient factors follow — age, BMI, smoking status, activity goals, and capacity to manage a surgical recovery.

That last point is frequently underweighted. AMIC and OCA both require approximately six weeks of protected weight-bearing and rehabilitation measured in months. Where surgical fitness is limited, or occupational circumstances make a prolonged recovery difficult, the ChondroFiller injection pathway — outpatient, same-day discharge, no general anaesthesia — may suit the clinical picture even where a surgical technique is technically applicable.

The three approaches are not interchangeable. ChondroFiller injection suits the smaller isolated defect with intact bone. AMIC suits the medium focal lesion where a single-stage surgical repair is appropriate. OCA provides structural depth that neither alternative can offer — at the cost of a more complex surgical profile and, in large or bipolar presentations, survivorship outcomes that form part of any honest consent discussion.

Determining which scenario applies requires imaging that characterises both cartilage and subchondral bone, alongside a consultant assessment. Lincolnshire Knee accepts patients without referral.

1. [1] AMIC Cartilage Repair in a Professional Soccer Player. (2012). https://doi.org/10.1155/2012/364342 https://doi.org/10.1155/2012/364342
2. [2] Does the AMIC® technique result in positive outcomes for the repair of cartilage lesions in the knee in adolescent patients?. (2025). https://doi.org/10.52628/91.2.14344 https://doi.org/10.52628/91.2.14344
3. [3] Implantation of ChondroFiller Liquid® as a Scaffold Material for the Treatment of Chondral Lesions of the Knee Joint. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
4. [4] The biomechanical and functional outcomes of fresh osteochondral allograft for the knee: A systematic review. (2025). https://doi.org/10.1016/j.jcot.2025.102983 https://doi.org/10.1016/j.jcot.2025.102983
5. [5] Midterm Survivorship and Clinical Outcomes in Fresh Osteochondral Allograft Transplantation for the Treatment of Large Bipolar Lesions of the Knee. (2025). https://doi.org/10.1177/03635465241313139 https://doi.org/10.1177/03635465241313139
6. [6] Osteochondral Allograft Transplantation as a Salvage Procedure After Failed Index Cartilage Surgery of the Knee: A Systematic Review. (2025). https://doi.org/10.1177/03635465241238466 https://doi.org/10.1177/03635465241238466
7. [7] Single-Stage Arthroscopic Cartilage Repair With Chondrectomy and Implantation of a Templated Membrane Collagen Scaffold With Bone Marrow Aspirate Concentrate Augmentation (AMIC Plus). (2023). https://doi.org/10.1016/j.eats.2023.07.030 https://doi.org/10.1016/j.eats.2023.07.030
8. [8] Joint Preservation in Patients with Grade IV Osteoarthritis of the Knee: Use of an Acellular Collagen Scaffold (ChondroFiller® Liquid) and Blood Derived Stem Cell Rich Graft — A Prospective Controlled Trial. (2025). https://doi.org/10.29011/2575-9760.011360 https://doi.org/10.29011/2575-9760.011360
9. [9] Mid-term failure rates, timing, and mechanisms for osteochondral allograft transplantation in the knee. (2025). https://doi.org/10.1016/j.jor.2025.03.040 https://doi.org/10.1016/j.jor.2025.03.040